Otenaproxesul

Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase-1 and 2 (COX-1 and 2) . Otenaproxesul possesses antiinflammatory and antinociceptive activities[1][4].

Product Specifications

CAS Number

[1226895-20-0]

Product Name Alternative

ATB-346

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; COX

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ATB-346.html

Concentration

10mM

Purity

98.03

Solubility

DMSO : ≥ 51.6 mg/mL

Smiles

COC1=CC=C(C=C(C(C)C(OC2=CC=C(C(N)=S)C=C2)=O)C=C3)C3=C1

Molecular Formula

C21H19NO3S

Molecular Weight

365.45

Precautions

H315, H319, H335

References & Citations

[1]John L Wallace, et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346) . Br J Pharmacol. 2010 Mar;159 (6) :1236-46.|[2]Paola De Cicco, et al. ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo. Pharmacol Res. 2016 Dec;114:67-73.|[3]Bruno Schneider Herrera, et al. The H2S-releasing naproxen derivative, ATB-346, inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis. Med Gas Res. 2015 Feb 27;5:4.|[4]panelEduardoEkundi-Valentim, et al. P4 Antiinflammatory and antinociceptive effects of ATB-346, a gastric sparing hydrogen sulfide-releasing naproxen, in rats with carrageenan-induced knee joint synovitis. Nitric Oxide. Volume 27, Supplement 2, 15 September 2012, Page S13.